Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered question first ministerially corrected answering member label previous answer version answering member printed answering member label
tabling member	label

Search

1127334

registered interest
date	17/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Isotretinoin: Side Effects
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential health risks and psychiatric side-effects of the drug Roaccutane.
tabling member constituency	Newcastle-under-Lyme
tabling member printed	Paul Farrelly
uin	255661
answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>As with all medicines in the United Kingdom, the Medicines and Healthcare products Regulatory Agency continuously monitors the safety of isotretinoin-containing medicines. This includes reports of suspected adverse drug reactions submitted by healthcare professionals, patients and carers through the Yellow Card scheme, as well as published and unpublished data. As new evidence on safety emerges it is carefully evaluated and, where appropriate, product information is updated and advice for prescribers and patients is issued.</p><p>Specific assessments of possible psychiatric side effects associated with isotretinoin were considered by an Expert Working Group of the Commission on Human Medicines in 2005 and 2014. In addition, the risk of neuropsychiatric disorders was evaluated in a European review which was completed in 2018. This review concluded that the warnings in the product information for medicines containing isotretinoin regarding possible psychiatric adverse effects reflected what was known.</p><p>Since 1998, warnings regarding the possible risk of developing depression and other psychiatric side effects have been included in the product information for Roaccutane and the generic versions of isotretinoin (the Summary of Product Characteristics for healthcare professionals and the patient information leaflet). The product information for isotretinoin warns that treatment may be associated with possible psychiatric side effects, that particular care needs to be taken in patients with a history of depression; and that all patients on isotretinoin should be monitored for signs of depression and referred for appropriate treatment if necessary. It also states that stopping isotretinoin may not lead to improvement and therefore further psychiatric or psychological evaluation may be necessary.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 22/05/2019 16:42:43 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	1436 label Biography information for Paul Farrelly

1126623

registered interest
date	14/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Baby Care Units: Mental Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of the adequacy of long-term mental health support given to parents of babies discharged from neonatal units.
tabling member constituency	Lewisham, Deptford
tabling member printed	Vicky Foxcroft
uin	254232
answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>Perinatal mental health services are available to all parents, including parents of babies that have been discharged from neonatal units, when they need it.</p><p>In April 2019, NHS England confirmed that new and expectant mothers across the country are now able to access specialist mental health care in the area where they live. The rollout of specialist community services across the whole of England, means that those suffering from perinatal mental health problems are able to access high quality care much closer to home.</p><p> </p><p>The Five Year Forward View for Mental Health committed to invest £365 million from 2015/16 to 2020/21 in perinatal mental health services to ensure that, by 2020/21, at least 30,000 more women each year are able to access evidence-based specialist mental health care during the perinatal period.</p><p> </p><p>The NHS Long Term Plan includes a commitment for a further 24,000 women to be able to access specialist perinatal mental health care by 2023/24. Specialist care will also be available from preconception to 24 months after birth, which will provide an extra year of support. Support will also be extended to fathers and partners of women accessing specialist perinatal mental health services and maternity outreach clinics.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 22/05/2019 16:41:06 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4491 label Biography information for Vicky Foxcroft

1126321

registered interest
date	13/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Gender Dysphoria: Children
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether they intend to publish the results of the research project started in 2011 by the NHS Gender Identity Development Service Early pubertal suppression in a carefully selected group of adolescents with gender identity disorder; and if not, whether they will arrange for the data gathered by that study to be made available to other researchers.
tabling member printed	Lord Lucas
uin	HL15681
answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>The research is an ethically approved study being carried out by the Tavistock and Portman NHS Foundation Trust since 2011, which is the largest provider of services for the alleviation of gender dysphoria in the United Kingdom.</p><p>The study will evaluate early pubertal suppression in a carefully selected group of adolescents with a clinical diagnosis of gender dysphoria. There are 44 young people taking part in the study.</p><p>The Tavistock and Portman NHS Foundation Trust has plans to publish the data <ins class="ministerial">on the blocker and cross-sex hormones, for those who were appropriate for this, as</ins><del class="ministerial">once</del> all of the young people in the study have reached <ins class="ministerial">this</ins><del class="ministerial">the</del> stage<ins class="ministerial">.</ins> <del class="ministerial">when a clinical decision is made about moving from pubertal suppressants to cross-sex hormones, which the Trust expects to occur in the next 12 months.</del></p> answering member printed Baroness Blackwood of North Oxford question first answered 22/05/2019 14:51:30 question first ministerially corrected 31/07/2019 15:30:59 answering member 4019 label Biography information for Baroness Blackwood of North Oxford previous answer version 119577 answering member printed Baroness Blackwood of North Oxford answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	1879 label Biography information for Lord Lucas